Literature DB >> 22075795

Risk factors, clinical features, and outcomes of toxoplasmosis in solid-organ transplant recipients: a matched case-control study.

Núria Fernàndez-Sabé1, Carlos Cervera, M Carmen Fariñas, Marta Bodro, Patricia Muñoz, Mercè Gurguí, Julián Torre-Cisneros, Pilar Martín-Dávila, Ana Noblejas, Oscar Len, Ana García-Reyne, José Luis Del Pozo, Jordi Carratalà.   

Abstract

BACKGROUND: Solid-organ transplant (SOT) recipients are considered to be at increased risk for toxoplasmosis. However, risk factors for this infection have not been assessed. The aim of this study was to determine the risk factors, clinical features, and outcomes of toxoplasmosis in SOT recipients.
METHODS: A multicenter, matched case-control study (1:2 ratio) was conducted between 2000 and 2009. Control subjects were matched for center, transplant type, and timing. Cases were identified from the hospitals' microbiology and transplantation program databases. Logistic regression was performed to identify independent risk factors.
RESULTS: Twenty-two cases (0.14%) of toxoplasmosis were identified among 15 800 SOTs performed in 11 Spanish hospitals, including 12 heart, 6 kidney, and 4 liver recipients. Diagnosis was made by seroconversion (n = 17), histopathologic examination (n = 5), polymerase chain reaction (n = 2), and autopsy (n = 2). In a comparison of case patients with 44 matched control subjects, a negative serostatus prior to transplantation was the only independent risk factor for toxoplasmosis (odds ratio, 15.12 [95% confidence interval, 2.37-96.31]; P = .004). The median time to diagnosis following transplantation was 92 days. Primary infection occurred in 18 (81.8%) cases. Manifestations included pneumonitis (n = 7), myocarditis (n = 5), brain abscesses (n = 5), chorioretinitis (n = 3), lymph node enlargement (n = 2), hepatosplenomegaly (n = 2), and meningitis (n =1). Five patients (22.7%) had disseminated disease. Crude mortality rate was 13.6% (3 of 22 patients).
CONCLUSIONS: Although uncommon, toxoplasmosis in SOT patients causes substantial morbidity and mortality. Seronegative recipients are at high risk for developing toxoplasmosis and should be given prophylaxis and receive careful follow-up.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075795     DOI: 10.1093/cid/cir806

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

Review 1.  Neurologic complications after liver transplantation.

Authors:  Saša A Zivković
Journal:  World J Hepatol       Date:  2013-08-27

Review 2.  The neurology of solid organ transplantation.

Authors:  J David Avila; Saša Živković
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 3.  Pentamidine in Pneumocystis jirovecii prophylaxis in heart transplant recipients.

Authors:  Adem Ilkay Diken; Ozlem Erçen Diken; Onur Hanedan; Seyhan Yılmaz; Ata Niyazi Ecevit; Emir Erol; Adnan Yalçınkaya
Journal:  World J Transplant       Date:  2016-03-24

Review 4.  Opportunistic infections of the central nervous system in the transplant patient.

Authors:  Bruce A Cohen; Valentina Stosor
Journal:  Curr Neurol Neurosci Rep       Date:  2013-09       Impact factor: 5.081

Review 5.  Epidemiology of and diagnostic strategies for toxoplasmosis.

Authors:  Florence Robert-Gangneux; Marie-Laure Dardé
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

6.  Molecular diagnosis of toxoplasmosis in immunocompromised patients: a 3-year multicenter retrospective study.

Authors:  Florence Robert-Gangneux; Yvon Sterkers; Hélène Yera; Isabelle Accoceberry; Jean Menotti; Sophie Cassaing; Marie-Pierre Brenier-Pinchart; Christophe Hennequin; Laurence Delhaes; Julie Bonhomme; Isabelle Villena; Emeline Scherer; Frédéric Dalle; Feriel Touafek; Denis Filisetti; Emmanuelle Varlet-Marie; Hervé Pelloux; Patrick Bastien
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

7.  Infectious Complications After Liver Transplantation.

Authors:  Maria Del Pilar Hernandez; Paul Martin; Jacques Simkins
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-11

8.  Taking the challenge: A protocolized approach to optimize Pneumocystis pneumonia prophylaxis in renal transplant recipients.

Authors:  K F Urbancic; F Ierino; E Phillips; P F Mount; A Mahony; J A Trubiano
Journal:  Am J Transplant       Date:  2017-10-03       Impact factor: 8.086

Review 9.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

10.  Acute Liver Failure Due to Toxoplasmosis After Orthotopic Liver Transplantation.

Authors:  Nicholas Baldwin; Meagan Gray; Chirag R Patel; Sameer Al Diffalha
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.